Eurofins Scientific has announced it is combining its competencies with MWG Operon and Medigenomix to provide the most complete suite of genomics services in the market, under the brand name Eurofins Genomics.
Eurofins MWG Operon is a pioneer and key provider of genomic services, and Eurofins Medigenomix, the group’s competence centre for applied solutions in DNA & RNA analysis, are being brought together.
The new brand represents the genomics division of the Eurofins Scientific Group, and consolidates its market presence as a provider of full genomic services in various market segments. Eurofins Genomics operates leading R&D and production sites in the US (Huntsville, AL and Louisville, KY), Germany (Ebersberg), India (Bangalore) and Japan (Tokyo).
Eurofins Genomics services are tailored for pharma, diagnostics, agriculture, food, biotechnology and research applications worldwide. Together with the international laboratory network of the Eurofins Group, Eurofins Genomics has an outstanding team of experts utilising a broad range of state-of-the-art technologies to provide the highest quality of service in DNA & RNA oligonucleotides, custom DNA and next generation sequencing, gene synthesis and molecular biology, as well as genotyping and gene expression.
Eurofins Genomics senior vice-president Bruno Poddevin said: "After years of continuous growth within the Eurofins Scientific network, I am extremely happy to align our traditional brands, ‘MWG’, ‘Operon’ and ‘Medigenomix’, under a single brand which is synonymous with our commitment to be first-in-class provider of genomic services. This underlines our goal to strengthen our global position as the leading supplier of applied genomics solutions in the future."